INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 158 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2021. The put-call ratio across all filers is 1.46 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $738,485 | +141.5% | 39,832 | +44.1% | 0.00% | – |
| Q2 2023 | $305,765 | +15.3% | 27,646 | +40.0% | 0.00% | – |
| Q1 2023 | $265,283 | -6.5% | 19,753 | -13.9% | 0.00% | – |
| Q4 2022 | $283,867 | +2.9% | 22,948 | +16.0% | 0.00% | – |
| Q3 2022 | $276,000 | -52.7% | 19,791 | -53.2% | 0.00% | – |
| Q2 2022 | $584,000 | -43.9% | 42,322 | -33.9% | 0.00% | -100.0% |
| Q1 2022 | $1,041,000 | -32.6% | 63,994 | -32.5% | 0.00% | 0.0% |
| Q4 2021 | $1,544,000 | +12.9% | 94,811 | +3.0% | 0.00% | 0.0% |
| Q3 2021 | $1,368,000 | -27.0% | 92,092 | -1.8% | 0.00% | 0.0% |
| Q2 2021 | $1,873,000 | -15.9% | 93,796 | -2.7% | 0.00% | -50.0% |
| Q1 2021 | $2,226,000 | +1.1% | 96,431 | +8.2% | 0.00% | 0.0% |
| Q4 2020 | $2,201,000 | -12.6% | 89,115 | +46.7% | 0.00% | 0.0% |
| Q3 2020 | $2,518,000 | +31.4% | 60,736 | +51.8% | 0.00% | 0.0% |
| Q2 2020 | $1,916,000 | +267.8% | 40,000 | +383.4% | 0.00% | +100.0% |
| Q1 2020 | $521,000 | -47.6% | 8,275 | +3.0% | 0.00% | 0.0% |
| Q4 2019 | $995,000 | +79.3% | 8,032 | -3.9% | 0.00% | – |
| Q3 2019 | $555,000 | -8.9% | 8,361 | +9.3% | 0.00% | -100.0% |
| Q2 2019 | $609,000 | -73.5% | 7,653 | -62.7% | 0.00% | -50.0% |
| Q1 2019 | $2,297,000 | +14.4% | 20,533 | +3.1% | 0.00% | 0.0% |
| Q4 2018 | $2,007,000 | +97.2% | 19,914 | +147.2% | 0.00% | +100.0% |
| Q3 2018 | $1,018,000 | +74.3% | 8,056 | +15.7% | 0.00% | 0.0% |
| Q2 2018 | $584,000 | +110.1% | 6,962 | +54.3% | 0.00% | – |
| Q1 2018 | $278,000 | +16.8% | 4,511 | +10.7% | 0.00% | – |
| Q4 2017 | $238,000 | -87.5% | 4,074 | -74.0% | 0.00% | -100.0% |
| Q2 2017 | $1,901,000 | +10.5% | 15,699 | +3.1% | 0.00% | 0.0% |
| Q1 2017 | $1,721,000 | +2.1% | 15,222 | -1.9% | 0.00% | 0.0% |
| Q4 2016 | $1,686,000 | -33.9% | 15,520 | +0.2% | 0.00% | -33.3% |
| Q3 2016 | $2,550,000 | +27.4% | 15,491 | +10.4% | 0.00% | 0.0% |
| Q2 2016 | $2,002,000 | +13.8% | 14,033 | +2.4% | 0.00% | 0.0% |
| Q1 2016 | $1,760,000 | -14.2% | 13,705 | -0.2% | 0.00% | 0.0% |
| Q4 2015 | $2,052,000 | -9.9% | 13,734 | -0.0% | 0.00% | -25.0% |
| Q3 2015 | $2,278,000 | -12.8% | 13,738 | +27.0% | 0.00% | 0.0% |
| Q2 2015 | $2,611,000 | -11.8% | 10,818 | +3.0% | 0.00% | 0.0% |
| Q1 2015 | $2,960,000 | +80.7% | 10,500 | 0.0% | 0.00% | +33.3% |
| Q4 2014 | $1,638,000 | -32.8% | 10,500 | +1.9% | 0.00% | -25.0% |
| Q3 2014 | $2,438,000 | +0.0% | 10,300 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $2,437,000 | -45.2% | 10,300 | -23.6% | 0.00% | -50.0% |
| Q1 2014 | $4,445,000 | – | 13,478 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |